{"id":870264,"date":"2025-08-04T15:46:46","date_gmt":"2025-08-04T19:46:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/"},"modified":"2025-08-04T15:46:46","modified_gmt":"2025-08-04T19:46:46","slug":"berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/","title":{"rendered":"Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A\/S (NYSE: NVO) After Class Action Filing"},"content":{"rendered":"
\n

PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC<\/a> announces a class action lawsuit against\u00a0Novo Nordisk A\/S (NYSE: NVO) <\/strong>(\u201cNovo\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or otherwise acquired publicly traded securities of Novo from\u00a0May 7, 2025 through July 28, 2025 <\/strong>(the \u201cClass Period\u201d).<\/p>\n

\n
\n Investor Deadline:<\/em>
\n <\/strong>
\n Investors who purchased or acquired Novo securities during the Class Period may, no later than <\/em>
\n
\n September 30, 2025<\/em>
\n <\/strong>
\n , seek to be appointed as a lead plaintiff representative of the class. To learn your rights,<\/em>
\n
\n CLICK HERE<\/strong>
\n <\/a>.<\/p>\n

Novo, headquartered in Denmark, is a global pharmaceutical company. According to the Complaint, the Company is alleged to have understated the impact of the\u00a0personalization exception\u00a0to the compounded GLP-1 exclusion, which has allowed persistent use of compounded alternatives to Novo\u2019s pharmaceutical products. Novo allegedly overstated the likelihood that patients using less expensive compounded drugs would switch to its branded products, thus greatly overstating the Company\u2019s ability to sustain long-term growth.<\/p>\n

On\u00a0July 29, 2025, Novo announced it was lowering its sales and profit outlook for fiscal 2025. The Company cited slower-than-expected growth for both\u00a0Wegovy\u00ae\u00a0and\u00a0Ozempic\u00ae, attributing the guidance revision to continued competition from compounded GLP-1 products.<\/p>\n

Following this announcement, Novo\u2019s stock price dropped from a closing price of\u00a0$69.00\u00a0per share on July 28, 2025, to\u00a0a close of $53.94\u00a0per share on July 29\u2014a decline of approximately\u00a021.83%\u00a0in a single day.<\/p>\n

\n
\n If you are a Novo investor and would like to learn more about this action, <\/em>
\n <\/strong>
\n
\n
\n CLICK HERE<\/em>
\n <\/strong>
\n <\/a>
\n
\n or please contact Berger Montague: Andrew Abramowitz at <\/em>
\n <\/strong>
\n
\n
\n aabramowitz@bergermontague.com<\/em>
\n <\/strong>
\n <\/a>
\n
\n or (215) 875-3015, or Caitlin Adorni at <\/em>
\n <\/strong>
\n
\n
\n cadorni@bergermontague.com<\/em>
\n <\/strong>
\n <\/a>
\n
\n or (267)764-4865.<\/em>
\n <\/strong>\n <\/p>\n

\n About Berger Montague<\/strong>
\n
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation<\/a> since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.<\/p>\n

\n For more information or to discuss your rights, please contact:<\/strong>
\n
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com<\/a><\/p>\n

Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC announces a class action lawsuit against\u00a0Novo Nordisk A\/S (NYSE: NVO) (\u201cNovo\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or otherwise acquired publicly traded securities of Novo from\u00a0May 7, 2025 through July 28, 2025 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased or acquired Novo securities during the Class Period may, no later than September 30, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Novo, headquartered in Denmark, is a global pharmaceutical company. According to the Complaint, the Company is alleged to have understated the impact of the\u00a0personalization exception\u00a0to the compounded GLP-1 … <\/p>\n

Continue reading “Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A\/S (NYSE: NVO) After Class Action Filing”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-870264","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBerger Montague PC Investigating Claims on Behalf of Novo Nordisk A\/S (NYSE: NVO) After Class Action Filing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A\/S (NYSE: NVO) After Class Action Filing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC announces a class action lawsuit against\u00a0Novo Nordisk A\/S (NYSE: NVO) (\u201cNovo\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or otherwise acquired publicly traded securities of Novo from\u00a0May 7, 2025 through July 28, 2025 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased or acquired Novo securities during the Class Period may, no later than September 30, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Novo, headquartered in Denmark, is a global pharmaceutical company. According to the Complaint, the Company is alleged to have understated the impact of the\u00a0personalization exception\u00a0to the compounded GLP-1 … Continue reading "Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A\/S (NYSE: NVO) After Class Action Filing"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-04T19:46:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNTc3NiM3MDgwNzMyIzIwODI5NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A\\\/S (NYSE: NVO) After Class Action Filing\",\"datePublished\":\"2025-08-04T19:46:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\\\/\"},\"wordCount\":368,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNTc3NiM3MDgwNzMyIzIwODI5NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\\\/\",\"name\":\"Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A\\\/S (NYSE: NVO) After Class Action Filing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNTc3NiM3MDgwNzMyIzIwODI5NjI=\",\"datePublished\":\"2025-08-04T19:46:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNTc3NiM3MDgwNzMyIzIwODI5NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNTc3NiM3MDgwNzMyIzIwODI5NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A\\\/S (NYSE: NVO) After Class Action Filing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A\/S (NYSE: NVO) After Class Action Filing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/","og_locale":"en_US","og_type":"article","og_title":"Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A\/S (NYSE: NVO) After Class Action Filing - Market Newsdesk","og_description":"PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC announces a class action lawsuit against\u00a0Novo Nordisk A\/S (NYSE: NVO) (\u201cNovo\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or otherwise acquired publicly traded securities of Novo from\u00a0May 7, 2025 through July 28, 2025 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased or acquired Novo securities during the Class Period may, no later than September 30, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Novo, headquartered in Denmark, is a global pharmaceutical company. According to the Complaint, the Company is alleged to have understated the impact of the\u00a0personalization exception\u00a0to the compounded GLP-1 … Continue reading \"Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A\/S (NYSE: NVO) After Class Action Filing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-04T19:46:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNTc3NiM3MDgwNzMyIzIwODI5NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A\/S (NYSE: NVO) After Class Action Filing","datePublished":"2025-08-04T19:46:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/"},"wordCount":368,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNTc3NiM3MDgwNzMyIzIwODI5NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/","name":"Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A\/S (NYSE: NVO) After Class Action Filing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNTc3NiM3MDgwNzMyIzIwODI5NjI=","datePublished":"2025-08-04T19:46:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNTc3NiM3MDgwNzMyIzIwODI5NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNTc3NiM3MDgwNzMyIzIwODI5NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-novo-nordisk-a-s-nyse-nvo-after-class-action-filing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A\/S (NYSE: NVO) After Class Action Filing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/870264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=870264"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/870264\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=870264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=870264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=870264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}